Published in Int J Radiat Oncol Biol Phys on May 19, 2011
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck. AJR Am J Roentgenol (2013) 1.21
Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer (2014) 1.18
Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep (2014) 1.00
Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis. Oral Oncol (2012) 0.90
Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approaches. Cancer Biol Ther (2011) 0.86
Applications and limitations of radiomics. Phys Med Biol (2016) 0.85
Amide proton transfer-weighted imaging of the head and neck at 3 T: a feasibility study on healthy human subjects and patients with head and neck cancer. NMR Biomed (2014) 0.83
Dynamic contrast-enhanced MRI, diffusion-weighted MRI and (18)F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol (2016) 0.79
Evaluation of Head and Neck Tumors with Functional MR Imaging. Magn Reson Imaging Clin N Am (2016) 0.79
Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time. Springerplus (2015) 0.79
MRI of metastasis-permissive microenvironments. Future Oncol (2011) 0.78
Texture analysis on parametric maps derived from dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer. World J Radiol (2016) 0.78
Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations. Cancer Imaging (2016) 0.78
Functional imaging for radiotherapy treatment planning: current status and future directions-a review. Br J Radiol (2015) 0.77
The principal of dynamic contrast enhanced MRI, the method of pharmacokinetic analysis, and its application in the head and neck region. Int J Dent (2012) 0.77
The use of dynamic tracer concentration in veins for quantitative DCE-MRI kinetic analysis in head and neck. PLoS One (2013) 0.77
The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective. Br J Radiol (2017) 0.76
Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical Settings. Front Oncol (2017) 0.75
Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. Br J Cancer (2016) 0.75
DCE-MRI for Pre-Treatment Prediction and Post-Treatment Assessment of Treatment Response in Sites of Squamous Cell Carcinoma in the Head and Neck. PLoS One (2015) 0.75
Modelling tumour volume variations in head and neck cancer: magnetic resonance imaging contribution for patients undergoing induction chemotherapy. Acta Otorhinolaryngol Ital (2016) 0.75
Multimodality functional imaging using DW-MRI and (18)F-FDG-PET/CT during radiation therapy for human papillomavirus negative head and neck squamous cell carcinoma: Meixoeiro Hospital of Vigo Experience. World J Radiol (2017) 0.75
Parametric contrast-enhanced ultrasound as an early predictor of radiation-based therapeutic response for lymph node metastases of nasopharyngeal carcinoma. Mol Clin Oncol (2014) 0.75
Functional magnetic resonance imaging techniques and their development for radiation therapy planning and monitoring in the head and neck cancers. Quant Imaging Med Surg (2016) 0.75
Contemporary Diagnostic Imaging of Oral Squamous Cell Carcinoma - A Review of Literature. Pol J Radiol (2017) 0.75
Biological imaging in clinical oncology: radiation therapy based on functional imaging. Int J Clin Oncol (2016) 0.75
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (1997) 4.55
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol (2006) 2.72
Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res (2007) 2.08
Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist (2008) 2.00
Causes and effects of heterogeneous perfusion in tumors. Neoplasia (1999) 1.76
Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol (2002) 1.69
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med (1995) 1.65
Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol (2009) 1.40
Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol (2006) 1.39
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2007) 1.33
Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.32
Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys (2008) 1.24
Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res (2005) 1.21
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging (2009) 1.19
Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck (2001) 1.16
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys (2009) 1.16
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol (2009) 1.15
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res (1998) 1.14
Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging (1999) 1.14
Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res (2001) 1.12
Prediction of survival in patients with head and neck cancer. Head Neck (2001) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck (2009) 1.07
Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys (2008) 1.05
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol (2002) 1.04
Head and neck cancer: recent advances and new standards of care. J Clin Oncol (2006) 1.02
Usefulness of standard deviation on the histogram of ultrasound as a quantitative value for hepatic parenchymal echo texture; preliminary study. Ultrasound Med Biol (2006) 1.01
Heterogeneity analysis of Gd-DTPA uptake: improvement in breast lesion differentiation. J Comput Assist Tomogr (1999) 0.97
Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas. Eur J Surg Oncol (2009) 0.95
Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol (1999) 0.94
Tumor volume: an independent predictor of outcome for laryngeal cancer. J Comput Assist Tomogr (1999) 0.92
Association of 8p23 deletions with poor survival in head and neck cancer. Otolaryngol Head Neck Surg (2001) 0.89
Prognostic factors in squamous cell carcinoma of the head and neck. Onkologie (2002) 0.87
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys (2007) 0.87
Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer (1999) 0.86
FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol (2008) 0.86
Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma. Am J Clin Oncol (2002) 0.84
Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg (2009) 0.82
Functional imaging of head and neck cancers. Curr Opin Oncol (2009) 0.81
Head and neck cancer emerging strategies: advances and new challenges. Curr Opin Oncol (2009) 0.78
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
The value of resident presentations at scientific meetings. Laryngoscope (2013) 3.48
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Practice patterns in choice of left double-lumen tube size for thoracic surgery. Anesth Analg (2008) 3.25
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
Intrapartum elective cesarean delivery: a previously unrecognized clinical entity. Obstet Gynecol (2004) 2.79
Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys (2005) 2.75
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
A quantitative measurement of the human somatic mutation rate. Cancer Res (2005) 2.55
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid (2014) 2.31
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg (2007) 2.28
Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 2.23
The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. JPEN J Parenter Enteral Nutr (2009) 2.16
A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol (2010) 2.15
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One (2007) 2.14
DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene (2003) 2.10
Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg (2002) 2.08
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing. Cell Cycle (2010) 2.06
Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2005) 2.04
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin (2005) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97
Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer (2003) 1.94
Use of information resources by patients with cancer and their companions. Cancer (2004) 1.93
Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.91
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun (2002) 1.85
Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest (2005) 1.85
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2011) 1.80
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer (2006) 1.79
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol (2011) 1.78
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2010) 1.77
Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg (2003) 1.74
Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer (2004) 1.74
Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med (2002) 1.73
Preserving electron spin coherence in solids by optimal dynamical decoupling. Nature (2009) 1.73
Critical care medicine use and cost among Medicare beneficiaries 1995-2000: major discrepancies between two United States federal Medicare databases. Crit Care Med (2007) 1.73
Management of well-differentiated thyroid carcinoma presenting within a thyroglossal duct cyst. J Surg Oncol (2002) 1.73
Endoscopic retrograde dilation of completely occlusive esophageal strictures. Ann Thorac Surg (2006) 1.71
Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther (2007) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Leukocytosis and increased risk of atrial fibrillation after general thoracic surgery. Ann Thorac Surg (2006) 1.70
Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol (2010) 1.70
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med (2007) 1.69
Causes of death in long-term survivors of head and neck cancer. Cancer (2014) 1.68
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed (2005) 1.65
Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med (2008) 1.65
Craniofacial and intracranial manifestations of langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol (2008) 1.64
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.64
Head and neck cancers. J Natl Compr Canc Netw (2011) 1.64
Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study. Cancer (2007) 1.63
Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology (2004) 1.60
ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res (2004) 1.60
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2009) 1.58
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol (2010) 1.58